Related Experiment Videos
Brachytherapy of choroidal melanomas
Summary
Radioactive plaque brachytherapy offers safe and effective treatment for uveal melanoma, with survival rates comparable to enucleation. Careful radiation dosing is crucial to minimize ocular toxicity and preserve vision.
Area of Science:
- Ophthalmology
- Oncology
- Radiation Therapy
Background:
- Surgical management, primarily enucleation, has historically been the standard for uveal melanoma, yielding 5- and 10-year survival rates of 63% and 43%, respectively.
- The introduction of radioactive plaque brachytherapy, particularly with iodine-125, has provided an alternative treatment with comparable survival outcomes.
Discussion:
- While plaque brachytherapy shows excellent survival rates (77% at 5 years for iodine-125), prospective randomized trials are lacking, leaving management decisions unsettled.
- Ocular radiation toxicity is a concern, with high doses to the fovea impacting visual acuity. Scleral necrosis is a potential late complication requiring intervention in about 10% of cases.
Key Insights:
- Malignant melanoma of the uvea can be safely treated with radioactive plaques, demonstrating survival rates similar to enucleation.
- Radiation dose to the fovea is critical; doses under 500 Gy preserve better visual acuity (90% retain 20/200 or better) compared to higher doses (52% retain 20/200 or better).
Outlook:
- Further research, including prospective randomized trials like the Collaborative Ocular Melanoma Study, is needed to definitively establish optimal treatment strategies.
- Continued monitoring for late effects such as scleral necrosis is essential for long-term patient management and to refine treatment protocols.